{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:23:52Z","timestamp":1760077432094},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ygyno.2016.12.024","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T17:03:29Z","timestamp":1483635809000},"page":"531-535","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma"],"prefix":"10.1016","volume":"144","author":[{"given":"Stuart R.","family":"Pierce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica E.","family":"Stine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola A.","family":"Gehrig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura J.","family":"Havrilesky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeles A.","family":"Secord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna C.","family":"Snavely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic T.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.12.024_bb0005","article-title":"Cancer statistics, 2016","author":"Siegel","year":"2016","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00000478-198203000-00002","article-title":"Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma","volume":"6","author":"Hendrickson","year":"1982","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0015","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.ajog.2007.08.075","article-title":"Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths","volume":"198","author":"Ueda","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ygyno.2006.01.014","article-title":"Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?","volume":"102","author":"Chan","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0025","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ygyno.2004.04.009","article-title":"Association between uterine serous carcinoma and breast cancer","volume":"94","author":"Gehrig","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1006\/gyno.2001.6445","article-title":"Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma","volume":"83","author":"Geisler","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cncr.27720","article-title":"BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma","volume":"119","author":"Pennington","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0045","first-page":"1457","article-title":"Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence","volume":"57","author":"Ford","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2016.1820","article-title":"Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations","author":"Shu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","article-title":"Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers","volume":"1","author":"Fornander","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0060","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1093\/jnci\/91.19.1654","article-title":"Tamoxifen therapy for breast cancer and endometrial cancer risk","volume":"91","author":"Bernstein","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0065","article-title":"Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment","volume":"24","author":"Creasman","year":"1997","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(00)02677-5","article-title":"Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen","volume":"356","author":"Bergman","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0075","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study","volume":"97","author":"Fisher","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ygyno.2013.02.023","article-title":"Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial","volume":"129","author":"Brinton","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0085","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ygyno.2008.08.035","article-title":"Relationship between tamoxifen use and high risk endometrial cancer histologic types","volume":"112","author":"Bland","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0090","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/gyno.2000.6003","article-title":"Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?","volume":"79","author":"Goshen","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0095","first-page":"142","article-title":"Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma","volume":"115","author":"Geisler","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0100","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ygyno.2013.05.020","article-title":"Disparities in uterine cancer epidemiology, treatment, and survival among African Americans in the United States","volume":"130","author":"Long","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0105","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2003.11.009","article-title":"BRCA germline mutations in Jewish women with uterine serous papillary carcinoma","volume":"92","author":"Lavie","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/gyno.2000.6082","article-title":"Risk of endometrial carcinoma associated with BRCA mutation","volume":"80","author":"Levine","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0115","first-page":"28","article-title":"BRCA1 germline mutations in women with uterine serous papillary carcinoma","volume":"96","author":"Lavie","year":"2000","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0120","first-page":"596","article-title":"BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum","volume":"92","author":"Bandera","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.7150\/jca.8412","article-title":"Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study","volume":"5","author":"Chen","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0130","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","article-title":"High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients","volume":"11","author":"Magriples","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(02)09962-2","article-title":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial","volume":"360","author":"Cuzick","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2016.12.024_bb0140","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1994.1271","article-title":"Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features","volume":"55","author":"Barakat","year":"1994","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.12.024_bb0145","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/cncr.23005","article-title":"Quality of life in survivors of multiple primary cancers compared with cancer survivor controls","volume":"110","author":"Gotay","year":"2007","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816316882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,14]],"date-time":"2018-07-14T20:18:48Z","timestamp":1531599528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816316882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0090825816316882"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.12.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}